Biscayne Neurotherapeutics Stock

biscayneneuro.comHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $9MM

Biscayne Neurotherapeutics is a clinical-stage biotechnology company developing novel therapies for difficult-to-treat neurological disorders.

Register To Buy and Sell Shares

For more details on financing and valuation for Biscayne Neurotherapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Biscayne Neurotherapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Biscayne Neurotherapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Jared Mendel
Director, Finance and Administration
Stephen Collins Ph.D
Chief Executive Officer & President
Samuel Reich
Executive Chairman & Co-Founder

Board Members

Warren Lammert
Carey Ng Ph.D
Mesa Verde Venture Partners
Samuel Reich
Zafrira Avnur Ph.D
Quark Venture
Updated on: Dec 10, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.